12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement ...
Patrizia Cavazzoni, formerly the top regulator of the drug division of the FDA, will join Pfizer as chief medical officer.
NSM Insurance Group announced it has signed a definitive agreement to sell its U.S. commercial insurance division to New Mountain Capital, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results